Related references
Note: Only part of the references are listed.Efficacy and safety of mineralocorticoid receptors in mild to moderate arterial hypertension
Francesco Pelliccia et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2015)
Randomized, Double-Blind, Placebo-Controlled Trial of Spironolactone for Hypokalemia in Continuous Ambulatory Peritoneal Dialysis Patients
Somchai Yongsiri et al.
THERAPEUTIC APHERESIS AND DIALYSIS (2015)
Interdialytic Weight Gain and Cadiovascular Outcome in Incident Hemodialysis Patients
Mi Jung Lee et al.
AMERICAN JOURNAL OF NEPHROLOGY (2014)
A Comorbidity Index for Mortality Prediction in Chinese Patients with ESRD Receiving Hemodialysis
Jinn-Yang Chen et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2014)
Effects of Spironolactone on Dialysis Patients With Refractory Hypertension: A Randomized Controlled Study
Xiaoying Ni et al.
JOURNAL OF CLINICAL HYPERTENSION (2014)
Spironolactone Reduces Cardiovascular and Cerebrovascular Morbidity and Mortality in Hemodialysis Patients
Yoshihiro Matsumoto et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
The aldosterone receptor antagonist spironolactone prevents peritoneal inflammation and fibrosis
Lei Zhang et al.
LABORATORY INVESTIGATION (2014)
Stroke and cerebrovascular diseases in patients with chronic kidney disease
Kazunori Toyoda et al.
LANCET NEUROLOGY (2014)
Cardiovascular complications in atypical haemolytic uraemic syndrome
Marina Noris et al.
NATURE REVIEWS NEPHROLOGY (2014)
Aldosterone Blockade in Chronic Kidney Disease
Jamie S. Hirsch et al.
SEMINARS IN NEPHROLOGY (2014)
Cardiovascular magnetic resonance risk stratification in patients with clinically suspected myocarditis
Julia Schumm et al.
JOURNAL OF CARDIOVASCULAR MAGNETIC RESONANCE (2014)
Stroke in Dialysis and Chronic Kidney Disease
Albert Power
BLOOD PURIFICATION (2013)
Mineralocorticoid receptors modulate vascular endothelial function in human obesity
Moon-Hyon Hwang et al.
CLINICAL SCIENCE (2013)
Fibrosis and cardiac function in obesity: a randomised controlled trial of aldosterone blockade
Wojciech Kosmala et al.
HEART (2013)
Spironolactone improves endothelial and cardiac autonomic function in non heart failure hemodialysis patients
Panayota Flevari et al.
JOURNAL OF HYPERTENSION (2013)
A new approach to improve the specificity of flow-mediated dilation for indicating endothelial function in cardiovascular research
Greg Atkinson et al.
JOURNAL OF HYPERTENSION (2013)
Aldosterone and Mortality in Hemodialysis Patients: Role of Volume Overload
Szu-Chun Hung et al.
PLOS ONE (2013)
Mineralocorticoid Receptor Blockade in Chronic Kidney Disease
Andrew S. Bomback et al.
BLOOD PURIFICATION (2012)
Left Ventricular Dysfunction Assessed by Cardiac Time Interval Analysis Among Different Geometric Patterns in Untreated Hypertension
Kunitsugu Takasaki et al.
CIRCULATION JOURNAL (2012)
Probing the Mechanisms of Intradialytic Hypertension: A Pilot Study Targeting Endothelial Cell Dysfunction
Jula K. Inrig et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2012)
A Randomized, Double-Blind, Placebo-Controlled Trial of Spironolactone on Carotid Intima-Media Thickness in Nondiabetic Hemodialysis Patients
Antonio Vukusich et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2010)
Long-Term Low-Dose Spironolactone Therapy Is Safe in Oligoanuric Hemodialysis Patients
Yoshihiro Matsumoto et al.
CARDIOLOGY (2009)
Fluid Retention Is Associated With Cardiovascular Mortality in Patients Undergoing Long-Term Hemodialysis
Kamyar Kalantar-Zadeh et al.
CIRCULATION (2009)
Left ventricular hypertrophy in renal disease: beyond preload and afterload
Eberhard Ritz
KIDNEY INTERNATIONAL (2009)
Evaluation of endothelial dysfunction: Flow-mediated dilation
Hasan Korkmaz et al.
ENDOTHELIUM-JOURNAL OF ENDOTHELIAL CELL RESEARCH (2008)
Gynecomastia
Glenn D. Braunstein
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Effect of spironolactone on K+ homeostasis and ENaC expression in lymphocytes from chronic hemodialysis patients
L Michea et al.
KIDNEY INTERNATIONAL (2004)
Safety of low-dose spironolactone administration in chronic haemodialysis patients
P Saudan et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2003)
Effect of dialysis dose and membrane flux in maintenance hemodialysis.
G Eknoyan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure - Insights from the Randomized Aldactone Evaluation Study (RALES)
F Zannad et al.
CIRCULATION (2000)
Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure
CAJ Farquharson et al.
CIRCULATION (2000)
Share Paper
